Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q1 FY2026 Earnings Presentation
32 slides from Shilpa Medicare's earnings presentation, Aug 13, 2025
Slide 1: Exchange filing cover letter for investor presentation
Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Date: 13th August, 2025 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 To, Corporate Relationsh
Slide 2: Shilpa Medicare Ltd 1QFY26 Earnings Presentation
Shilpa Medicare Ltd 1QFY26 Earnings Presentation Date: 13th August 2025
Slide 3: Safe Harbour
Safe Harbour Certain statements in this document may be forward - looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ
Slide 4: Shilpa Medicare at a glance
Shilpa Medicare at Established in 1987, we have 35+ years track record a glance Existing Business Segments: API , Formulation, CDMO, Biologics Emerging Businesses: NDDS, ADC and Recombinant Human Albumin 10+ Regulatory approved manufacturing + R&D facilities (incl Analytical Lab) 400+ R&D Personnel
Slide 5: Key operating verticals
Key operating verticals API Formulations Biologics 11% 1QFY26 Revenue 30% contribution 59% ▪ Shilpa Pharma Lifesciences ▪ Shilpa Medicare ▪ Shilpa Biologicals Legal ▪ Shilpa Therapeutics ▪ Shilpa Biocare Entities ▪ FTF Pharma Areas of ▪ Oncology ▪ Tablets/Capsules ▪ NBE Operation ▪ Non-Oncology ▪ In
Slide 6: Management Commentary
Management Commentary The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the U.S.—Bortezomib RTU— reinforcing our R&D-driven approach and delivering differentiated products that enhance ease of
Slide 7: 1QFY26 Performance
sS 1QFY26 Performance
Slide 8: 1Q FY26 – Financial Highlights
1Q FY26 – Financial Highlights Highest Quarterly EBITDA 1Q FY26 (Consolidated) Revenue Break-up (INR crs) Particulars (INR cr) 1QFY26 1QFY25 YoY 4QFY25 QoQ Others, 7.0 Total Revenue 328 302 9% 338 (3%) Biologicals, 37.0 2% Gross Profit 248 209 19% 234 6% 11% GP Margin 76% 69% 700 bps 69% 700 bps For
Slide 9: Consolidated Performance
Consolidated Performance (INR in Cr.) Revenues EBITDA and Margins 30% 98 27% 25% 83 84 302 338 328 1QFY25 4QFY25 1QFY26 1QFY25 4QFY25 1QFY26 PBT and Margins PAT and Margins 14% 15% 13% 10% 50 10% 43 47 5% 29 33 14 1QFY25 4QFY25* 1QFY26 1QFY25 4QFY25* 1QFY26 8 *Adjusted to Exceptional Item
Slide 10: Financial Summary
Financial Summary ROCE Gross Block (INR crs) 8.8% 9.1% 8% 6.2% 1,991 2,004 2.0% 1,538 1,587 1,670 1.0% FY21 FY22 FY23 FY24 FY25 1QFY26* FY22 FY23 FY24 FY25 1QFY26 Net Debt to EBITDA (x) Net Capex (INR crs) 6.7 5.8 3.4 3 1.6 1.6 331 225 216 172 70 FY21 FY22 FY23 FY24 FY25 1QFY26* FY22 FY23 FY24 FY25
Slide 11: API Business
API Business 10
Slide 12: Multiple growth drivers with strong order book
Multiple growth drivers with strong order book (INR in Cr.) ▪ 1QFY26 Revenue growth (including captive) came in at ~25% YoY. All our key segments 223 181 226 reported healthy growth driven by strong order book and higher captive commitments ▪ Newly increased capacities for key products viz. 13 17 UD
Slide 13: API – Ongoing Developments
API – Ongoing Developments API Molecules CDMO Polymer and Peptide ▪ Commercial-Scale Manufacturing Capacities ▪ 2 programs expected to commercialize in FY27, NDA filed ▪ Commercial supplies started of large polymer project commenced operations for High-Demand ▪ Secured a new contract for the supply
Slide 14: Formulations Business
Formulations Business 13
Slide 15: Pipeline monetization to drive growth
Pipeline monetization to drive growth (INR in Cr.) ▪ All 3 approved and launched NDAs have limited competition. More NDAs will be filed in coming 132 103 98 quarters ▪ Launched our 2nd NDA viz. Bortezomib RTU Subcutaneous in US, scale up expected in FY26 24 ▪ Pemetrexed gaining market share in US, w
Slide 16: FDF – Update on key assets
FDF – Update on key assets SMLNUD07 SMLTDP08 SMLODF010 SMLTOP09 SMLINJ011 SMLTDP012 SMLOSD014 NorUDCA Rotigotine Tadalafil Film ▪ Received historic ▪ Transdermal Patch for ▪ Topical lotion for ▪ First company to ▪ Long Acting Injection ▪ An innovative delivery ▪ A unique patient- approval for treatm
Slide 17: Filings – Formulations
Filings – Formulations Formulations – Regulatory Filings Pending Approved 30 81 10 618 291 17 6 74 327 13 4 7 US ANDA and NDA EU Canada ROW Robust regulatory filings to strengthen the base for growth in the formulation segment Our ODF & TDP manufacturing Unit 6 received EIR approval from US FDA and
Slide 18: CDMO Business
CDMO Business 17
Slide 19: CDMO – Strong capabilities in various technologies
CDMO – Strong capabilities in various technologies Very strong capability Strong capability Developing capability Negligible capability Indian CDMOs Global CDMOs Shilpa Medicare Peer 1 Peer 2 Peer 3 Global Peer 1 Global Peer 2 Global Peer 3 Specialized technologies Small molecule Peptide Monoclonal
Slide 20: Robust business model encompassing various stages
Robust business model encompassing various stages Value chain Late stage development & Commercial Development & Clinical supplies stages Manufacturing Clinical development Commercial Phases Pre-Clinical Development Registration & Supplies Manufacturing ▪ Drug metabolism, pharmacokinetics (DMPK) ▪ Ph
Slide 21: Comprehensive CDMO Development
Comprehensive CDMO Development Long term manufacturing and supply Unicycive Therapeutics Inc’s agreement with SML. SML is receiving significant milestone Oxylanthanum Carbonate (OLC) is a income spanning over various stages Potential best-in-class product being viz. filing, approval and launch of th
Slide 22: Biologics & NBE
Biologics & NBE 21
Slide 23: Biologics – Growth envisioned on 4 pillars
Biologics – Growth envisioned on 4 pillars Integrated CDMO Biologics Novel Biologics ADC Platform @Dharwad ▪ Adalimumab: India market sees ▪ Novel MAB (oncology): Term ▪ Five active Novel Biologic ▪ Shilpa’s First ADC biosimilar is growth, 24-month shelf life approved sheet signed with mAbTree; cell
Slide 24: Why Recombinant Human Albumin?
Why Recombinant Human Albumin ? Predictable & assured All raw materials used High quality/Purity supply – Product in in the production are Meets Global yeast (Pichia pastoris) free from animal standards by fermentation sources Freedom from Best in class potential productivity – makes contamination t
Slide 25: Shilpa's Recombinant Human Albumin
Shilpa’s Recombinant Human Albumin Key highlights ▪ Entered into a strategic partnership with Orion Corporation for commercialization in Europe region for therapeutic use Shilpa’s novel ▪ Under this agreement, Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa’s
Slide 26: Outlook
Outlook FDF CDMO API Biologics NDA – Pemetrexed and Bortezomib Two NCE projects to commercialize in Multiple complex API launches, growth Strong Biosimilar pipeline with various FY27 in Specialty portfolio, coupled with large assets completing clinical trails, Hybrid – Nilotinib (limited capacity ex
Slide 27: Manufacturing Capabilities – API & Biocare
Manufacturing Capabilities – API & Biocare API Unit I - Raichur API Unit II - Raichur Biocare - Kadechur • Manufacturing and R&D Centre Onco, Non-Onco NCE, APIs, Peptide and • Fully automated integrated facility with DCS Capabilities • Small molecule development, Linker, GalNAc Polymers, Manufacturi
Slide 28: Manufacturing Capabilities – Formulations & Biologics
Manufacturing Capabilities – Formulations & Biologics Formulations - Jadcherla Formulations - Bangalore Biologics - Dharwad End-to-end services, from development to commercial manufacturing of microbial & Capabilities OSD tablets and capsules; Injectables – dry Fully automated facility for Transderm
Slide 29: Financials
Financials 28
Slide 30: Profit & Loss Consolidated
Profit & Loss Consolidated Particulars (INR cr) 1QFY26 1QFY25 YoY 4QFY25 QoQ Revenues 328 302 9% 338 (3%) Gross Profit 248 209 19% 234 6% Gross Margin % 76% 69% 69% Employee Cost 82 72 14% 71 15% Other Expenses 68 54 26% 79 -14% EBITDA 98 83 18% 84 17% EBITDA Margin % 30% 27% 25% Finance Cost 19 24
Slide 31: Earnings call Details
Earnings call Details Shilpa Medicare 1QFY26 Results Conference Call to be held August 13, 2025, Wednesday at 17:00 IST Details of Earnings Conference Call +91 22 6280 1130 Universal Access +91 22 7115 8031 The number listed above is universally accessible from all networks and all countries Interna
Slide 32: Thank You!
Shilpa Medicare Limited Monish Shah +91 2249748754 THANK YOU! monish.shah@vbshilpa.com 31